Clinical Trial

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Study acronym: NEO-COMBATXL
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This multicenter study examines the safety and feasibility of the combination of neoadjuvant XL092 and cemiplimab prior to surgical resection in participants with wild-type (WT) anaplastic thyroid cancer (ATC) that has a BRAF mutation (BRAF V600E).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-18; most recent amendment 2025-11-03.
Status change: Not Yet Recruiting → Recruiting 2025-06-03
Trial Details
NCT Number NCT06902376
Lead Sponsor UNC Lineberger Comprehensive Cancer Center
Collaborators: Regeneron Pharmaceuticals, Exelixis
Conditions Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors
Enrollment 12 participants
Start Date 2025-06-03
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-11-05